The mutational status of KRAS (exon 2) and BRAF (p.V600E) in CRC and EGFR (p.L858R and deletions in exon 19) in NSCLC had been previously assessed by PCR in the context of daily practice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.